Aktiesnakken — December 2009
-
men jeg ved ikke hvordan vi får fat i rapporten og tror vel næppe at den har recepter, eller andre news som kan forklare hvorfor 3 mill
-
aktier skal skifte hænder og sende kursen 20% op
-
Targeting underserved chronic lymphocytic leukemia patients may enhance Arzerra's uptake in the market; gains FDA approval
-
da vi jo talte meget om vores bekymringer på vej ned. tænker jeg at kosmos tillader os vores spekulationer på vej op. Men jeg ka ta fejl
-
ikke første gang og bestemt ikke sidste
-
Aka??
-
sig be be
-
hvad? porterhouse steaks...eller genmab news?
-
bare gør det
-
-
be be
-
kan også være en ged
-
arrhhh fuck... næste link på samme søgning sendte mig til proinvestor
-
been there done thar
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind